In the next three years, the overall size of the city's biomedical industry will grow from less than 40 billion yuan to 100 billion yuan, establishing the city’s dominant position in the country's biomedical industry. At the kick-off ceremony for the Beijing Biomedical Industry Leapfrogging Development Project (G20 Project) held on April 23, the reporter learned that in the next three years, the city will adopt policy support, financial incentives, build a series of new initiatives such as public R&D platforms, and promote biomedical sciences. Industry has become a pillar industry supporting the economic and social development of the capital.

According to Yan Aoluo, director of the Beijing Municipal Science and Technology Commission, the focus of the G20 project is to support a group of large-scale backbone enterprises, cultivate a group of innovative companies with potential, introduce a group of domestic and foreign key enterprises, and give priority to supporting the R&D of companies that seriously affect the health of the citizens. Drugs and devices related to dangerous diseases. At the launch ceremony, the first 23 companies that were shortlisted for the G20 project were announced. These companies will become the core strength of Beijing's industry scale of RMB 100 billion in the future.